OR WAIT null SECS
The program and proposed integrations could produce $15 million in savings annually.
GoodRx and Boehringer Ingelheim are partnering on copay cost savings on several leading medications for type 2 diabetes and chronic obstructive pulmonary disease (COPD).
“Patients with type 2 diabetes or chronic obstructive pulmonary disease can now easily enroll in manufacturer-sponsored copay programs for Boehringer Ingelheim’s leading portfolio of medications to help reduce their out-of-pocket costs, with additional medications that may be added to the integration in the future,” GoodRx said in a press release.
This integration and other proposed integrations have the potential to deliver around $15 million in available savings a year, according to GoodRx.
Medications included in the copay program include: Jardiance(empagliflozin), Synjardy (empagliflozin/metformin HCI), Synjardy XR, Spiriva Respimat(tiotropium bromide), Stiolto Respimat(tiotropium bromide and olodaterol), and Combivent Respimat(ipratropium bromide and albuterol).
“As insurance deductibles increase, fewer medications are covered by insurance, and more restrictions are placed on the medications that are covered, patients are left carrying more of the economic burden,” Bansi Nagji, president of Healthcare at GoodRx, said in a statement. “The integration of Boehringer Ingelheim’s savings programs will help lower the affordability barrier for patients so they can better access the medications they need.”
“We look forward to expanding our collaborative partnership with GoodRx so we can help more people living with chronic conditions find the appropriate savings program and lower their out-of-pocket costs,” said Chris Marsh, senior vice president of market access at Boehringer Ingelheim.
GoodRx earlier this year developed a similar program for insulin and other product with the pharma manufacturer Sanofi, with the potential to save Americans up to $260 million or more on first fill costs in 2021, based on GoodRx estimates.